S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Hookipa Pharma Stock Forecast, Price & News

+0.28 (+2.44 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $11.76
50-Day Range
MA: $11.62
52-Week Range
Now: $11.76
Volume99,825 shs
Average Volume138,570 shs
Market Capitalization$256.97 million
P/E RatioN/A
Dividend YieldN/A
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.


HOOK Feb 2021 17.500 call
January 24, 2021 |  uk.finance.yahoo.com
HOOKIPA Pharma (HOOK) in Focus: Stock Moves 8.4% Higher
January 20, 2021 |  finance.yahoo.com
HOOKIPA (HOOK) Surges: Stock Moves 8.6% Higher
December 8, 2020 |  finance.yahoo.com
Is HOOK A Good Stock To Buy Now?
December 8, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HOOK
Year FoundedN/A



Sales & Book Value

Annual Sales$11.94 million
Book Value$5.46 per share


Net Income$-43,040,000.00
Net Margins-232.00%


Market Cap$256.97 million
Next Earnings Date3/18/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.22 out of 5 stars

Medical Sector

804th out of 1,958 stocks

Pharmaceutical Preparations Industry

398th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.28 (+2.44 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

Is Hookipa Pharma a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Hookipa Pharma stock.
View analyst ratings for Hookipa Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Hookipa Pharma?

Wall Street analysts have given Hookipa Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hookipa Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Hookipa Pharma's next earnings date?

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Hookipa Pharma

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) released its earnings results on Thursday, November, 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.11. The firm had revenue of $4.04 million for the quarter, compared to analyst estimates of $4.16 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 39.58% and a negative net margin of 232.00%.
View Hookipa Pharma's earnings history

How has Hookipa Pharma's stock price been impacted by COVID-19?

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HOOK shares have increased by 27.1% and is now trading at $11.76.
View which stocks have been most impacted by COVID-19

What price target have analysts set for HOOK?

5 brokers have issued 1-year price targets for Hookipa Pharma's stock. Their forecasts range from $16.00 to $25.00. On average, they anticipate Hookipa Pharma's stock price to reach $20.20 in the next year. This suggests a possible upside of 71.8% from the stock's current price.
View analysts' price targets for Hookipa Pharma
or view top-rated stocks among Wall Street analysts.

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the following people:
  • Mr. Joern Aldag, Pres, CEO & Director (Age 60)
  • Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
  • Dr. Reinhard Kandera, CFO & Director (Age 50)
  • Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
  • Mrs. Nina Waibel, Communications & Investor Relations Mang.

Who are some of Hookipa Pharma's key competitors?

What other stocks do shareholders of Hookipa Pharma own?

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Artal Group S.A. (4.35%), BlackRock Inc. (2.94%), Northern Trust Corp (0.69%), Samsara BioCapital LLC (0.59%), Monashee Investment Management LLC (0.41%) and Nuveen Asset Management LLC (0.24%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr.
View institutional ownership trends for Hookipa Pharma

Which major investors are selling Hookipa Pharma stock?

HOOK stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, ETF Managers Group LLC, and Barclays PLC. Company insiders that have sold Hookipa Pharma company stock in the last year include Igor Matushansky, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma
or view top insider-selling stocks.

Which major investors are buying Hookipa Pharma stock?

HOOK stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Monashee Investment Management LLC, Engineers Gate Manager LP, JPMorgan Chase & Co., Tudor Investment Corp Et Al, BlackRock Inc., State of Wisconsin Investment Board, and Samsara BioCapital LLC. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma
or or view top insider-buying stocks.

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $11.76.

How much money does Hookipa Pharma make?

Hookipa Pharma has a market capitalization of $256.97 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

How many employees does Hookipa Pharma have?

Hookipa Pharma employs 56 workers across the globe.

What is Hookipa Pharma's official website?

The official website for Hookipa Pharma is www.hookipapharma.com.

Where are Hookipa Pharma's headquarters?

Hookipa Pharma is headquartered at 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.